Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous MelanomaSylvia M. Lee(Fred Hutch Cancer Center), Charles Lance Cowey(Baylor University)Clinical Cancer ResearchDecember 30, 202410.1158/1078-0432.ccr-24-1478Cited by 7SaveCiteExport RISWatch citationsRelated PapersNon-viral precision T cell receptor replacement for personalized cell therapy|Nature|2022|276Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors|Cancer Discovery|2024|108